Trial · NCT05862233
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete remission rate at Week 76 | Week 76 | The proportion of participants who achieved complete remission (CR) based on Urine Protein-to-Creatinine Ratio (UPCR) at week 76. |
| Secondary | Complete Remission rate at Week 52. | Week 52 | The proportion of participants who achieved CR based on UPCR at week52 (key secondary endpoints) |
| Secondary | Overall remission rate at Week 52 and 76. | Week 52 and 76 | The proportion of participants who achieved overall remission(OR) based on UPCR at week 52 and week76. |
| Secondary | Complete remission rate and Overall remission rate at Week 24 and 104. | Week 24 and 104 | The proportion of participants who achieved CR and OR based on UPCR at week 24 and week 104. |
| Secondary | Complete remission rate and Overall remission rate at Week 24，52，76 and 104. | Week 24，52，76 and 104 | The proportion of participants who achieved CR or OR as assessed by the Investigators based on 24-hour urine protein at week 24, week 52, week 76 and week 104. |
| Secondary | Time to Treatment Failure or Relapse after Overall remission | Up to 104 weeks | Time to Treatment Failure or Relapse after Complete or Partial Remission |
| Secondary | Change in efficacy indicators | Baseline to Week 104 | Change in anti-PLA2R Autoantibody Titer, UPCR, eGFR, 24-hour urine protein and ALB |
| Secondary | Change in quality of life | Baseline to Week 104 | Mean Change in T-score from Baseline in the EQ5D Scale at Week 104 |
| Secondary | Percentage of Participants with Adverse Events (AEs) | up to 104 weeks | Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 |
| Secondary | Percentage of Participants with AEs of Special Interest (AESIs) | Up to 104 weeks | |
| Secondary | Peripheral B-cell Counts at Specified Timepoints | Up to 104 weeks | |
| Secondary | Serum Concentrations of MIL62 at Specified Timepoints | Up to 104 weeks | |
| Secondary | Incidence of ADAs during the study | Up to 104 weeks |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05862233/registered